ME02189B - Farmaceutski dozni oblici sa kontrolisanim oslobađanjem - Google Patents

Farmaceutski dozni oblici sa kontrolisanim oslobađanjem

Info

Publication number
ME02189B
ME02189B MEP-2015-116A MEP2015116A ME02189B ME 02189 B ME02189 B ME 02189B ME P2015116 A MEP2015116 A ME P2015116A ME 02189 B ME02189 B ME 02189B
Authority
ME
Montenegro
Prior art keywords
pharmaceutical dosage
sustained
matrix formulation
dosage forms
controlled release
Prior art date
Application number
MEP-2015-116A
Other languages
English (en)
Inventor
Haiyong Hugh Huang
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of ME02189B publication Critical patent/ME02189B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (1)

1. Čvrsti oralni farmaceutski dozni oblik sa produženim oslobađanjem koji sadrži višeslojnu formulaciju matrice sa produženim oslobađanjem sa strukturom tipa sendviča ili polu sendviča, a formulacija matrice sa produženim oslobađanjem se sastoji od (1) prve kompozicije koja obrazuje prvi sloj koji sadrži aktivnu materiju formulacije matrice sa produženim oslobađanjem koja sadrži: (a) bar jedan polietilen oksid koji ima na osnovu reoloških merenja, približnu molekulsku masu od bar 1000 000; i (b) bar jednu aktivnu materiju; i (2) druge kompozicije koja obrazuje drugi sloj bez aktivne materije formulacije matrice sa produženim oslobađanjem koja sadrži bar jedan poletilen oksid.
MEP-2015-116A 2011-03-25 2012-03-22 Farmaceutski dozni oblici sa kontrolisanim oslobađanjem ME02189B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161467824P 2011-03-25 2011-03-25
PCT/IB2012/000595 WO2012131463A2 (en) 2011-03-25 2012-03-22 Controlled release pharmaceutical dosage forms
EP20120717468 EP2688556B1 (en) 2011-03-25 2012-03-22 Controlled release pharmaceutical dosage forms

Publications (1)

Publication Number Publication Date
ME02189B true ME02189B (me) 2016-02-20

Family

ID=46018006

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-116A ME02189B (me) 2011-03-25 2012-03-22 Farmaceutski dozni oblici sa kontrolisanim oslobađanjem

Country Status (24)

Country Link
US (1) US20140056979A1 (me)
EP (1) EP2688556B1 (me)
JP (1) JP5964940B2 (me)
KR (1) KR101619579B1 (me)
CN (1) CN103547259A (me)
AU (1) AU2012235878B2 (me)
BR (1) BR112013024585A8 (me)
CA (1) CA2831218C (me)
CY (1) CY1116579T1 (me)
DK (1) DK2688556T3 (me)
ES (1) ES2544735T3 (me)
HR (1) HRP20150835T1 (me)
HU (1) HUE026981T2 (me)
IL (1) IL228441B (me)
ME (1) ME02189B (me)
MX (1) MX350875B (me)
PH (1) PH12013501994A1 (me)
PL (1) PL2688556T3 (me)
PT (1) PT2688556E (me)
RS (1) RS54152B1 (me)
SI (1) SI2688556T1 (me)
SM (1) SMT201500209B (me)
WO (1) WO2012131463A2 (me)
ZA (1) ZA201307862B (me)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100889069B1 (ko) 1999-10-29 2009-03-17 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU2738302A (en) 2000-10-30 2002-05-15 Euro Celtique Sa Controlled release hydrocodone formulations
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
ME02874B (me) 2010-12-22 2018-04-20 Purdue Pharma Lp Obloženi dozni oblici sa kontrolisanim oslobađanjem otporni na zloupotrebu
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
KR102082529B1 (ko) 2012-04-17 2020-02-27 퍼듀 퍼머 엘피 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
BR112015000150A2 (pt) 2012-07-06 2017-06-27 Egalet Ltd composições farmacêuticas dissuasoras de abuso de liberação controlada
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
JP2020526500A (ja) 2017-06-30 2020-08-31 パーデュー、ファーマ、リミテッド、パートナーシップ 治療方法及びその剤形
CA3073570C (en) 2017-08-31 2025-07-08 Purdue Pharma L.P. Delayed-release oral opioid formulations comprising an anionic surfactant and polyethylene oxide
EP3727384A4 (en) 2017-12-20 2021-11-03 Purdue Pharma L.P. ABUSE-DISSUASIVE MORPHINE SULPHATE FORMES

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950007907B1 (ko) * 1992-09-01 1995-07-21 동국제약 주식회사 치주질환 치료용 막형 국소약물송달제제
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5634702A (en) 1995-09-27 1997-06-03 Fistonich; Juraj Hands free waste container having a closed cover that automatically opens when the container is moved outside its cabinet enclosure
DE60123384T2 (de) * 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
AU2738302A (en) * 2000-10-30 2002-05-15 Euro Celtique Sa Controlled release hydrocodone formulations
AR049562A1 (es) * 2004-07-01 2006-08-16 Gruenenthal Gmbh Formas farmaceuticas orales, con liberacion controlada de opioides, protegidas frente al abuso y procedimiento para su preparacion
US7434308B2 (en) * 2004-09-02 2008-10-14 International Business Machines Corporation Cooling of substrate using interposer channels
KR20080005429A (ko) * 2005-04-19 2008-01-11 알자 코포레이션 트라마돌 및 가바펜틴을 포함하는 물질의 배합물
EP2019904A1 (en) * 2006-05-17 2009-02-04 Sandvik Intellectual Property AB A rock-drilling tool, a drill rod and coupling sleeve
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8241993B2 (en) * 2007-07-13 2012-08-14 Marvell World Trade Ltd. Method for shallow trench isolation
WO2009114648A1 (en) * 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CN101933907A (zh) * 2009-06-30 2011-01-05 北京天衡药物研究院 新型骨架缓释片及其制备方法

Also Published As

Publication number Publication date
CY1116579T1 (el) 2017-03-15
IL228441A0 (en) 2013-12-31
ZA201307862B (en) 2014-06-25
US20140056979A1 (en) 2014-02-27
WO2012131463A2 (en) 2012-10-04
JP2014510094A (ja) 2014-04-24
IL228441B (en) 2019-05-30
EP2688556B1 (en) 2015-05-06
SMT201500209B (it) 2015-10-30
AU2012235878B2 (en) 2015-10-15
BR112013024585A8 (pt) 2018-01-09
DK2688556T3 (en) 2015-08-03
NZ616600A (en) 2015-07-31
PT2688556E (pt) 2015-09-11
JP5964940B2 (ja) 2016-08-03
CA2831218C (en) 2017-01-17
PH12013501994A1 (en) 2013-12-02
CN103547259A (zh) 2014-01-29
HRP20150835T1 (hr) 2015-09-11
CA2831218A1 (en) 2012-10-04
WO2012131463A3 (en) 2012-11-29
HUE026981T2 (en) 2016-08-29
PL2688556T3 (pl) 2015-10-30
ES2544735T3 (es) 2015-09-03
RS54152B1 (sr) 2015-12-31
KR20130135973A (ko) 2013-12-11
MX2013010987A (es) 2014-10-13
KR101619579B1 (ko) 2016-05-10
AU2012235878A1 (en) 2013-05-02
SI2688556T1 (sl) 2015-09-30
MX350875B (es) 2017-09-19
EP2688556A2 (en) 2014-01-29

Similar Documents

Publication Publication Date Title
ME02189B (me) Farmaceutski dozni oblici sa kontrolisanim oslobađanjem
AR081760A1 (es) Una composicion farmaceutica para administracion oral que comprende acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico, un metodo para producir la misma, una tableta y una forma unitaria de dosificacion oral que la comprende y el uso de la misma para la fabricacion de un medicamento
ES2478264T3 (es) Glicerosomas y uso de estos en preparaciones farmacéuticas y cosméticas para aplicación tópica
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
ECSP14013168A (es) Tableta a prueba de manipulación que proporciona liberación de fármaco inmediato
EA201001244A1 (ru) Система доставки лекарственного средства со стабилизирующим эффектом
JP2010285439A5 (me)
WO2009074351A3 (en) Solid forms of tenofovir disoproxil
CU20080052A7 (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
EP2475427A4 (en) ACTRIIB ANTAGONISTS, THEIR DOSAGE AND APPLICATIONS THEREOF
AR072950A1 (es) Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad, composicion farmaceutica, articulo de fabricacion y envase
EP4209513A4 (en) BISPECIFIC ANTI-VEGF-ANTI-PD-L1 ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF AND RELATED USES
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BR112012024139A2 (pt) formulações farmacêuticas de camada dupla contendo agonistas e antagonistas de opióide.
EP2153831A4 (en) ANTIERMÜDUNGSMITTEL AND ORAL COMPOSITION, BOTH WITH ANDROGRAPHOLIDE AS ACTIVE INGREDIENTS
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
JP2015514739A5 (me)
CL2014003237A1 (es) Formulación farmacéutica estable que comprende un anticuerpo anti-dll4 (ligando tipo delta humano 4); y kit que comprende la composición en un envase e instrucciones.
ECSP10010683A (es) Una formulacion farmacéutica sólida
IT1401284B1 (it) Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
WO2011130834A8 (en) Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof
BR112014004753A2 (pt) formulação de liberação de multicamadas
MA50394A (fr) Formulations pharmaceutiques comprenant un agoniste de récepteur d'opioïde en tant que substances actives, leurs procédés de fabrication et leurs utilisations thérapeutiques
CL2008000092A1 (es) Compuestos derivados de 3-cianopiridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compustos; y su uso en el tratamiento del transtorno de la agregacion plaquetaria.